久久综合结合久久很很很97色,免费无码婬片AAAA片直播影院,四虎国产精品亚洲永久免费

產(chǎn)品名稱：8-氮鳥嘌呤 (Sigma)操作步驟
英文名字：8-Azaguanine
說明：作為鳥嘌呤類似物抑制嘌呤的生物合成。
特性：級別：Hybri-Max™
滅菌：γ-irradiated 射線照射
熔點：>300 ℃
內(nèi)毒素含量：≤100 EU/ml
溶解性：1vial溶于10ml滅菌的細胞培養(yǎng)基中，配成50×溶液，用時稀釋，于−20℃保存。
應(yīng)用：用作雜交瘤細胞培養(yǎng)應(yīng)用中的骨髓瘤選擇劑。
復(fù)原：10mL無菌細胞培養(yǎng)基可復(fù)原一小瓶本品。儲備液足以制備500mL培養(yǎng)基。10mg/瓶包裝的Z終工作濃度：130μM 8-氮鳥嘌呤。
8-氮鳥嘌呤 (Sigma)操作步驟產(chǎn)品應(yīng)用：
對于一些相對特殊的產(chǎn)品，我們會提供產(chǎn)品說明書，里面會對產(chǎn)品溶解性，及我們所能了解的產(chǎn)品應(yīng)用信息，實驗方案進行描述，您可以作為參考。對于常見試劑，因為應(yīng)用廣泛，一般不提供說明書。如果您在實驗過程中遇到了問題，歡迎與我們討論，我們將盡力幫您解決。
8-氮鳥嘌呤 (Sigma)操作步驟分裝及溶液配制：
您收到貨物后不要自己進行分包，因為分包環(huán)境、包裝材料等因素可能導(dǎo)致分包后的產(chǎn)品變質(zhì)；如您有特殊包裝要求，請在訂購時候與我們客服代表闡明，當(dāng)然價格會做適當(dāng)調(diào)整。對于開蓋后，長期未使用的，請務(wù)必重新密封好，建議Parafilm封口膜，并按照相應(yīng)儲存條件使用。如果放置時間過長，超過產(chǎn)品有效期，建議您重新購買，以免影響實驗質(zhì)量。
8-氮鳥嘌呤 (Sigma)操作步驟儲存條件：
大部分的試劑產(chǎn)品是比較穩(wěn)定的，只要您嚴格按照產(chǎn)品包裝或者說明書上的儲存條件進行儲存，*可以保證其在有效期內(nèi)的正常使用。一般常見儲存條件有零下XX攝氏度，2-8攝氏度，常溫等。特別提醒，對于某些酶類制品，如果儲存條件是2-8攝氏度，不要儲存在零下，否則容易失活，對于某些需要嚴格避光，防潮，充氮氣保護的，接觸空氣或者過分暴露非常容易氧化或者受潮變質(zhì)。
低溫儲存產(chǎn)品，運輸途中冷藏問題：
對于需要低溫儲存的產(chǎn)品，我們在運輸時候都會采用冷藏包裝，但是部分由于外界氣溫過高，運輸時間較長，對于普通冷藏包裝，途中可能會溫度升高，這些都是沒有問題的，因為這種普通冷藏只適用于那些短期內(nèi)（2周）高溫依然穩(wěn)定的產(chǎn)品，建議低溫的儲存條件，只是長期儲存時候的條件，您可以放心使用。對于某些特殊的產(chǎn)品，如抗體，我們會采用干冰冷藏包裝，確保全程低溫。公司都對產(chǎn)品性狀進行了嚴格的加速穩(wěn)定測試，行業(yè)經(jīng)驗豐富。
8-氮鳥嘌呤 (Sigma)操作步驟儲存條件：避光、干燥陰涼處封閉貯存,嚴禁與有毒、有害物品混放、混運。本品為非危險產(chǎn)品可按一般化學(xué)品運輸,輕搬動輕放,防止日曬、雨淋！受熱、受潮、受光后易喪失活力,保存期短,因此貯存和運輸條件比較苛刻。
CFN99181   http://www.chemfaces。。ｃｏｍ/natural/Rosiridin-CFN99181.html   C16H28O7   332.39   100462-37-1   Rosiridin   Monoterpenoids   >=98%   20mg
CFN99182   http://www.chemfaces。。ｃｏｍ/natural/Sophocarpine-CFN99182.html   C15H22N2O   246.35   145572-44-7   Sophocarpine   Alkaloids   >=98%   20mg
CFN99183   http://www.chemfaces。。ｃｏｍ/natural/Taxifolin-CFN99183.html   C15H12O7   304.25   17654-26-1   (+)-Taxifolin   Flavonoids   >=98%   20mg
CFN99184   http://www.chemfaces。。ｃｏｍ/natural/Artemether-CFN99184.html   C16H26O5   298.38   71963-77-4   Artemether   Sesquiterpenes   >=98%   20mg
CFN99187   http://www.chemfaces。。ｃｏｍ/natural/Curcumol-CFN99187.html   C15H24O2   236.35   4871-97-0   Curcumol   Sesquiterpenes   >=98%   20mg
CFN99190   http://www.chemfaces。。ｃｏｍ/natural/Caffeic-acid-CFN99190.html   C9H8O4   180.15   331-39-5   Caffeic acid   Phenylpropanoids   >=98%   20mg
CFN99191   http://www.chemfaces。。ｃｏｍ/natural/Chondroitin-sulfate-CFN99191.html   (C14H21NO14S)n       9007-28-7   Chondroitin sulfate   Miscellaneous   >=98%   20mg
CFN99192   http://www.chemfaces。。ｃｏｍ/natural/Lipoic-acid-CFN99192.html   C8H14O2S2   206.3   62-46-4   Lipoic acid   Miscellaneous   >=98%   20mg
CFN99193   http://www.chemfaces。。ｃｏｍ/natural/Glucosamine-sulfate-CFN99193.html   C6H15NO9S   277.25   29031-19-4   Glucosamine sulfate   Miscellaneous   >=98%   20mg
CFN99194   http://www.chemfaces。。ｃｏｍ/natural/D-Glucosamine-hydrochloride-CFN99194.html   C6H13NO5·HCl   215.63   66-84-2   D-Glucosamine hydrochloride   Miscellaneous   >=98%   20mg
CFN99195   http://www.chemfaces。。ｃｏｍ/natural/Rotundine-CFN99195.html   C21H25NO4   355.42   10097-84-4   Rotundine   Alkaloids   >=98%   20mg
CFN99196   http://www.chemfaces。。ｃｏｍ/natural/Triptolide-CFN99196.html   C20H24O6   360.40   38748-32-2   Triptolide   Diterpenoids   >=98%   20mg
CFN99197   http://www.chemfaces。。ｃｏｍ/natural/Tripdiolide-CFN99197.html   C20H24O7   376.40   38647-10-8   Tripdiolide   Diterpenoids   >=98%   20mg

manner.
p53/TP53 that are not targeted to the proteasome. Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to proteasomal degradation. Deubiquitinated by USP10, leading to its stabilization. Ubiquitinated by TRIM24, which leads to proteasomal degradation. Ubiquitination by TOPORS induces degradation. Deubiquitination by USP7, leading to stabilization. Isoform 4 is monoubiquitinated in an MDM2-independent manner.
Monomethylated at Lys-372 by SETD7, leading to stabilization and increased transcriptional activation. Monomethylated at Lys-370 by SMYD2, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity. Lys-372 monomethylation prevents interaction with SMYD2 and subsequent monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and EHMT2. Monomethylated at Lys-382 by SETD8, promoting interaction with L3MBTL1 and leading to repress transcriptional activity. Demethylation of dimethylated Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-mediated transcriptional activation.
Sumoylated by SUMO1.
DISEASE : Note=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximay 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma.
Defects in TP53 are a cause of esophageal cancer (ESCR) [MIM:133239].
Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers.
Defects in TP53 are involved in head and neck squamous cell carcinomas (HNSCC)
Defects in TP53 are a cause of lung cancer (LNCR) [MIM:211980]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.
Defects in TP53 are a cause of choroid plexus papilloma (CPLPA) [MIM:260500]. Choroid plexus papilloma is a slow-growing benign tumor of the choroid plexus that often invades the leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood.
Defects in TP53 are a cause of adrenocortical carcinoma (ADCC) [MIM:202300]. ADCC is a rare childhood tumor of the adrenal cortex. It occurs with increased frequency in patients with the Beckwith-Wiedemann syndrome and is a component tumor in Li-Fraumeni yndrome.
Similarity : Belongs to the p53 family.
Database links : NCBI Reference Sequence: NP_001119584.1
UniProtKB/Swiss-Prot: P04637.4
英文名稱 Anti-phospho-P53(Thr81)
中文名稱磷酸化腫瘤抑制基因P53抗體
別名 p53 (Phospho-Thr81); P53 (phospho T81); P53 (phospho Thr81); p-P53 (Thr81); p-P53 (T81); Widespread p53; Wtp53; Antigen NY-CO-13; Cellular tumor antigen p53; Cys 51 Stop; HGNC11998; LFS1; p53; p53 Cellular Tumor Antigen; p53 Tumor Suppressor; Phosphoprotein p53; TP53; Transformation related protein 53; TRP53; Tumor protein p53; Tumour Protein p53; P53_HUMAN; TP53.
濃度 1mg/1ml
規(guī) 格 0.1ml/100μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Chicken
產(chǎn)品類型一抗磷酸化抗體
研究領(lǐng)域腫瘤免疫學(xué) 信號轉(zhuǎn)導(dǎo) 細胞凋亡轉(zhuǎn)錄調(diào)節(jié)因子
蛋白分子量 predicted molecular weight: 43kDa
性狀 Lyophilized or Liquid
免疫原 KLH conjugated Synthesised phosphopeptide derived from human P53 around the phosphorylation site of Thr81
8-氮鳥嘌呤 (Sigma)操作步驟亞型 IgG
純化方法 affinity purified by Protein A
儲存液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）